All In MedTech

Device Trial Radar · NCT07648693

Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial

A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Safety and Effectiveness of the Resonova® CHORDS® Cerebral Protection System in Capturing and Removing Embolic Debris During Transcatheter Aortic Valve Replacement

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Oct 31, 2025

Primary completion

Sep 30, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Resonova (Shanghai) Medtech LimitedNot on our public-company list
Sponsor type
Industry
First posted
Jun 15, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, randomized controlled study. The goal of the study is to assess the safety and effectiveness of the Resonova® CHORDS® Cerebral Protection System in capturing and removing embolic debris during Transcatheter Aortic Valve Replacement (TAVR). A total of 240 eligible participants will be enrolled and randomized in a 1:1 ratio to undergo TAVR either with the CHORDS® Cerebral Protection System (Test group) or the Sentinel System (Control group).All the participants will be followed up at 30 days and 90 days post-procedure.

Conditions

  • Transcatheter Aortic Valve Replacement (TAVR)
  • Cerebral Vascular Accident (CVA)/Stroke

Interventions

  • CHORDS® Cerebral Protection SystemDevice

    Undergo TAVR procedure with the CHORDS® Cerebral Protection System

  • Sentinel Cerebral Protection SystemDevice

    Undergo TAVR procedure with Sentinel Cerebral Protection System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of freedom from Major Adverse Cardiac and Cerebrovascular Events (MACCE)Time frame: 30 days post-procedure
  2. Total new lesion volume (TLV, mm³) in protected territories(DW-MRI)Time frame: 2-7 days post-procedure

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital, Fudan University

    Shanghai, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Recruiting

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Recruiting

12 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.